Contribution of complement system on destabilization of liposomes composed of hydrogenated egg phosphatidylcholine in rat fresh plasma
- PMID: 1543704
- DOI: 10.1016/0005-2736(92)90087-3
Contribution of complement system on destabilization of liposomes composed of hydrogenated egg phosphatidylcholine in rat fresh plasma
Abstract
Large multilamellar vesicles (MLV) composed of hydrogenated egg phosphatidylcholine (HEPC), cholesterol (CH), and dicetyl phosphate (DCP) rapidly release part of an entrapped aqueous marker when incubated with fresh rat plasma and thus have severely limited usefulness as drug carriers. The mechanisms causing the instability of liposomes in plasma were investigated in this study. The leakage of liposomal constituents was completely inhibited by pre-heating at 56 degrees C for 30 min with plasma or by treating with EDTA, K-76COOH, or anti-C3 antiserum but was not inhibited with EGTA/MgCl2. These results indicated that the destabilization of liposomes in fresh rat plasma was induced by activation of the alternative complement pathway (ACP). Furthermore, the complement third component (C3) was detected from the liposomes incubated with fresh plasma by SDS-PAGE followed by Western blotting and immune detection. The C3b deposited on the liposomal surface via ACP was rapidly cleaved to iC3b. The results obtained in the present study suggest a possibility that the liposomes composed of HEPC (without any surface modification) may be effective carriers for macrophages because C3b and its degradative products, iC3b are related to the opsonic function on phagocytosis of foreign particles by macrophages.
Similar articles
-
Effect of serum components from different species on destabilizing hydrogenated phosphatidylcholine-based liposomes.Biol Pharm Bull. 1997 Aug;20(8):874-80. doi: 10.1248/bpb.20.874. Biol Pharm Bull. 1997. PMID: 9300134
-
Effect of cholesterol content in activation of the classical versus the alternative pathway of rat complement system induced by hydrogenated egg phosphatidylcholine-based liposomes.Int J Pharm. 2001 Aug 14;224(1-2):69-79. doi: 10.1016/s0378-5173(01)00737-2. Int J Pharm. 2001. PMID: 11472816
-
Complement dependent and independent liposome uptake by peritoneal macrophages: cholesterol content dependency.Biol Pharm Bull. 1998 Sep;21(9):969-73. doi: 10.1248/bpb.21.969. Biol Pharm Bull. 1998. PMID: 9781849
-
Effect of cetylmannoside modification on the alternative complement pathway activation by liposomes in rat serum.Biol Pharm Bull. 1995 Apr;18(4):581-5. doi: 10.1248/bpb.18.581. Biol Pharm Bull. 1995. PMID: 7655432
-
Species difference in correlation between in vivo/in vitro liposome-complement interactions.Biol Pharm Bull. 2001 Apr;24(4):439-41. doi: 10.1248/bpb.24.439. Biol Pharm Bull. 2001. PMID: 11305612
Cited by
-
Rates of systemic degradation and reticuloendothelial system uptake of calcein in the dipalmitoylphosphatidylcholine liposomes with soybean-derived sterols in mice.Pharm Res. 1995 Jan;12(1):49-52. doi: 10.1023/a:1016230518884. Pharm Res. 1995. PMID: 7724487
-
Thermosensitive sterically stabilized liposomes: formulation and in vitro studies on mechanism of doxorubicin release by bovine serum and human plasma.Pharm Res. 1995 Oct;12(10):1407-16. doi: 10.1023/a:1016206631006. Pharm Res. 1995. PMID: 8584472
-
Immunological risk of injectable drug delivery systems.Pharm Res. 2009 Jun;26(6):1303-14. doi: 10.1007/s11095-009-9855-9. Epub 2009 Feb 27. Pharm Res. 2009. PMID: 19247815 Review.
-
SN38-loaded <100 nm targeted liposomes for improving poor solubility and minimizing burst release and toxicity: in vitro and in vivo study.Int J Nanomedicine. 2018 May 10;13:2789-2802. doi: 10.2147/IJN.S158426. eCollection 2018. Int J Nanomedicine. 2018. PMID: 29785106 Free PMC article.
-
Clinical pharmacokinetics of cytarabine formulations.Clin Pharmacokinet. 2002;41(10):705-18. doi: 10.2165/00003088-200241100-00002. Clin Pharmacokinet. 2002. PMID: 12162758 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous